ADNI data is made available to researchers around the world. As such, there are many active research projects accessing and applying the shared ADNI data. To further encourage Alzheimer’s disease research collaboration, and to help prevent duplicate efforts, the list below shows the specific research focus of the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Anne Favan-Niven |
| Institution: | Washington University in St. Louis |
| Department: | Neurology |
| Country: | |
| Proposed Analysis: | We are requesting ADNI imaging, clinical, genomic, and biomarker data to build a dataset for identification of CSF samples to request from the ADNI Resource Allocation Committee (RAC). We propose to analyze a promising and novel panel of biomarkers to better define preclinical Alzheimer’s disease (AD). This panel is to include the current gold standard CSF biomarkers Aβ42, tau and ptau181, the promising biomarker amyloid PET imaging, and the novel biomarkers visinin-like protein-1 (VILIP-1) – a putative neuronal injury marker, and chitinase-3 like protein-1 (YKL-40) – a putative neuroinflammation marker. With the field of AD research looking to diagnose AD in the preclinical stages of disease, an expanded biomarker panel will likely increase the sensitivity and specificity of both diagnosis and prognosis. Our first goal is to build a combined dataset of ADNI 1, ADNI GO and ADNI 2 participants in order to identify which ADNI subjects have data that will be required for our biomarker panel analysis. We will use this information to calculate sample size and statistical power for an application to obtain CSF samples from the ADNI RAC. If our application to the RAC is approved, the data contained in this dataset will be combined with data from our analysis of VILIP-1 and YKL-40 to make a biomarker panel dataset. Analysis of the full biomarker panel proposed above will be carried out with this expanded dataset. We hope to confirm the findings by our group that VILIP-1 and YKL-40 are viable AD biomarkers in a large, independent cohort. We hope to also develop a detailed trajectory of these biomarkers in preclinical subjects to better identify early changes in the pathogenic process. |
| Additional Investigators | |
| Investigator's Name: | Courtney Sutphen |
| Proposed Analysis: | We are requesting ADNI imaging, clinical, genomic, and biomarker data to build a dataset for identification of CSF samples to request from the ADNI Resource Allocation Committee (RAC). We propose to analyze a promising and novel panel of biomarkers to better define preclinical Alzheimer’s disease (AD). This panel is to include the current gold standard CSF biomarkers Aβ42, tau and ptau181, the promising biomarker amyloid PET imaging, and the novel biomarkers visinin-like protein-1 (VILIP-1) – a putative neuronal injury marker, and chitinase-3 like protein-1 (YKL-40) – a putative neuroinflammation marker. With the field of AD research looking to diagnose AD in the preclinical stages of disease, an expanded biomarker panel will likely increase the sensitivity and specificity of both diagnosis and prognosis. Our first goal is to build a combined dataset of ADNI 1, ADNI GO and ADNI 2 participants in order to identify which ADNI subjects have data that will be required for our biomarker panel analysis. We will use this information to calculate sample size and statistical power for an application to obtain CSF samples from the ADNI RAC. If our application to the RAC is approved, the data contained in this dataset will be combined with data from our analysis of VILIP-1 and YKL-40 to make a biomarker panel dataset. Analysis of the full biomarker panel proposed above will be carried out with this expanded dataset. We hope to confirm the findings by our group that VILIP-1 and YKL-40 are viable AD biomarkers in a large, independent cohort. We hope to also develop a detailed trajectory of these biomarkers in preclinical subjects to better identify early changes in the pathogenic process. |